<DOC>
	<DOCNO>NCT01090336</DOCNO>
	<brief_summary>Background : Both prasugrel clopidogrel prescribe drug compete platelet inhibitor patient acute coronary syndrome ( ACS ) . Whether rate drug resistance/hyporesponsiveness lower prasugrel whether consistent early onset platelet inhibition may reduce infarct size patient ACS undergo early PCI remain , present , unknown . Study design/study population : This trial prospective , open-label , single centre observational trial . Patients receive either prasugrel ( 60mg ) clopidogrel ( 600mg ) discretion attend cardiologist . Patients exclusion criterion prasugrel exclude clopidogrel well . The study population include 80 subject moderate high-risk ACS , ie patient unstable angina ( UA ) non-ST-segment elevation MI ( NSTEMI ) TIMI risk score 3 high , within 72 hour onset symptom . In patient early PCI plan . Study objective/endpoint/methods : The primary objective trial evaluate whether rate hyporesponsiveness low prasugrel whether consistent early onset platelet inhibition may reduce infarct size ACS patient undergo early PCI . The primary endpoint rate drug resistance time index intervention . Optical impedance aggregometry use ADP ( 5 20 μM ) collagen ( 1 μg/ml ) platelet agonist use measure platelet aggregation . Addition specific antagonist aspirin mesamp probe use discriminate pharmacodynamic pharmacokinetic drug resistance . Secondary endpoint reduction myocardial infarct size determine post-interventional increase high sensitive TnT ( TnT h ) day follow index event reflect early , effective consistent inhibition platelet function . Tertiary endpoint composite clinical endpoint cardiovascular death , nonfatal MI , stroke urgent target vessel revascularization hospitalization 6 12 month . Safety endpoint TIMI major minor bleeding hospital stay 6 12 month include intracranial life-threatening bleeding .</brief_summary>
	<brief_title>Prasugrel Versus Clopidogrel Acute Coronary Syndrome ( ACS ) Undergoing Percutaneous Coronary Intervention ( PCI )</brief_title>
	<detailed_description>look</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Inclusion criterion : Patients unstable angina nonSTelevation myocardial infarction ischemic symptom last 10 minute occur within 72 hour randomization , A TIMI risk score 3 , Either STsegment deviation 1 mm elevate level cardiac biomarker necrosis . Legal age ( ≥18 ) competent mental condition provide write informed consent Patients weight &lt; 60 kg , age &gt; 75 year history TIA , stroke intracranial bleeding accord prasugrel contraindication Clinical status forbid inclusion ( eg cardiogenic shock time randomization , refractory ventricular arrhythmia , New York Heart Association class IV congestive heart failure etc ) Bleeding risk exclusion criterion include fibrinspecific nonfibrinspecific fibrinolytic therapy index event , active internal bleeding history bleed diathesis clinical finding judgment investigator associate increase risk bleed History hemorrhagic stroke , intracranial neoplasm , arteriovenous malformation , aneurysm Ischemic stroke within 3 month prior screen Oral anticoagulation INR great 1.5 time screen Platelet count less 100 000/mm3 time screen Anemia ( hemoglobin &lt; 10 g/dL ) time screen Prior/concomitant therapy thienopyridine daily treatment nonsteroidal antiinflammatory drug cyclooxygenase2 inhibitor General exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>platelet aggregation inhibition</keyword>
	<keyword>prasugrel</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>ACS</keyword>
</DOC>